Combining SBRT With ICIs Does Not Improve PFS, OS in Solid Tumors
Adding SBRT to treatment with immune checkpoint inhibitors did not improve outcomes in patients with advanced solid tumors.
Source: cancertherapyadvisor.com
Stay updated with breaking news from Tegen Kanker. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Adding SBRT to treatment with immune checkpoint inhibitors did not improve outcomes in patients with advanced solid tumors.
However, a post-hoc analysis adds to evidence suggesting that irradiating all metastatic lesions may improve survival in patients receiving immune checkpoint inhibitor monotherapy.
COVID-19 infection causes an increase in inflammatory factors in cancer patients over and above that due to the disease itself, which may promote tumor development and explain their worse outcomes.